Latest news


PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology

Posted on May 22, 2017

Oslo (Norway), 22 May 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and RXi Pharmaceuticals (NASDAQ: RXII) a biotechnology company focused on developing novel RNAi therapeutics for significant un-met needs, today announced that they are extending their preclinical research collaboration initiated April 7, 2015.  This extension is supported by a new preclinical […]

PCI Biotech to present at Bio€quity Europe

Posted on May 18, 2017

Oslo, Norway, May 18, 2017 – PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present the Company at Bio€quity Europe, an investor and partnering event. The event is taking place at Paris Marriot Rive Gauche Conference Center, France, 22-23 May 2017. Dr. Per Walday, […]

First quarter 2017 report and presentation

Posted on May 16, 2017

Oslo, 16 May 2017 – Please find enclosed the financial report and presentation for first quarter 2017. PCI Biotech Q1 2017 Report PCI Biotech Q1 2017 Presentation Highlights fimaCHEM Presentation of the Phase I data at The International Liver Congress and the Annual Meeting of the US Cholangiocarcinoma Foundation Interaction with authorities to determine fastest […]